The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Powershares Dynamic Biotechnology and Genome Portfolio

NYSE: PBE
Last

(U.S.) $45.14

Today's change+0.33 +0.74%
Updated November 22 3:59 PM -5GMT. Delayed by at least 15 minutes.
 

Powershares Dynamic Biotechnology and Genome Portfolio

NYSE: PBE
Last

(U.S.) $45.14

Today's change+0.33 +0.74%
Updated November 22 3:59 PM -5GMT. Delayed by at least 15 minutes.

Powershares Dynamic Biotechnology and Genome Portfolio up (U.S.)$0.33

Powershares Dynamic Biotechnology and Genome Portfolio closed up Wednesday by (U.S.)$0.33 or 0.74% to (U.S.)$45.14. Over the last five days, shares have gained 2.99% and 16.31% year to date. Shares have underperformed the S&P 500 by 11.11% during the last year.

Key company metrics

  • Open(U.S.) $44.92
  • Previous close(U.S.) $44.81
  • High(U.S.) $45.28
  • Low(U.S.) $44.92
  • Bid / Ask-- / --
  • YTD % change+16.31%
  • Volume66,865
  • Average volume (10-day)18,471
  • Average volume (1-month)17,015
  • Average volume (3-month)20,565
  • 52-week range(U.S.) $38.61 to (U.S.) $51.17
  • Beta1.45
  • Trailing P/E3.47×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.87%
  • Trailing EPS(U.S.) $13.01
Updated November 22 3:59 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+2,132.76%

Based on its net profit margin of 2,132.76%, Powershares Dynamic Biotechnology and Genome Portfolio is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:FinancialsIndustry:Investment Trusts

Latest Company News

    No News Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q2/2015Q4/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedApr 30, 201504/30/2015Oct 31, 201410/31/2014Apr 30, 201404/30/2014Oct 31, 201310/31/2013
Revenue2320
Total other revenue--------
Total revenue2320
Gross profit1210
Total cost of revenue1110
Total operating expense1111
Selling / general / administrative0000
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total0000
Operating income1200
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax28892740
Income after tax28892740
Income tax, total----00
Net income28892740
Total adjustments to net income--------
Net income before extra. items28892740
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items28892740
Inc. avail. to common incl. extra. items28892740
Diluted net income28892740
Dilution adjustment--------
Diluted weighted average shares119117
Diluted EPS excluding extraordinary itemsvalue per share2.6710.332.545.37
Dividends per sharevalue per share0.000.280.000.00
Diluted normalized EPSvalue per share2.6710.332.545.37